Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MEG.
- Who it may be relevant to
- Registry conditions: Patients Diagnosed With a Malignant Glioma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
With more than 3,000 new cases per year in France, malignant gliomas are the most common malignant brain tumors in adults. Treatment consists of surgical removal when possible. If this is not possible, a biopsy is performed to obtain a definitive anatomical and molecular diagnosis. Standard medical management after removal or biopsy is based on radio-chemotherapy. Despite this multimodal treatment, progression is the norm due to the invasive nature of these tumors. The prognosis remains very poor, with a median overall survival of around 18 months for glioblastomas. Recent preliminary data indicate that magnetoencephalography (MEG) recordings can identify functional heterogeneity within a glioma. Functional analysis of these two types of areas has shown that the expression of synaptogenic factors is increased in areas of high functional connectivity compared to areas of low functional connectivity. Areas of high functional connectivity are more aggressive and more resistant to treatment. In general, gliomas are characterized by a high degree of inter- and intra-tumoral heterogeneity. The latter has been well characterized at the transcriptomic level, and several distinct cell subpopulations have been described (classical, mesenchymal, proneural) This intra-tumoral heterogeneity is one of the factors contributing to resistance to current therapies, but it remains incompletely understood and explored. MEG is a tool capable of exploring intra- and inter-tumor heterogeneity from an electrophysiological perspective. This represents an original approach that will provide a better understanding of intra-tumor heterogeneity and lead to new therapeutic perspectives.
Interventions
- Device MEG
Eligible patients will undergo a complete Magnetoencephalography, of approximatively 45min
Primary outcome measures
- Assess the technical feasibility of studying tumor electrophysiological heterogeneity using magnetoencephalography (MEG) in a series of patients with glioma at the initial stage of treatment. [Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.]
Secondary outcome measures (2)
- Define the radiological characteristics of the different types of areas of interest identified by MEG by comparing MEG mapping and preoperative MRI (anatomical and functional). [Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.]
- Define the prognostic impact of ablation of areas with different electrophysiological properties, using an analysis that integrates MEG mapping data, post-operative MRI data, and survival data. [Time frame: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.]
Eligibility criteria
Inclusion criteria
- Male or female aged over 18
- With a newly diagnosed malignant glioma based on brain imaging
- Eligible for surgical removal
- Having given their consent
Exclusion criteria
- Contraindications to Magnetic resonance imaging (MRI) (claustrophobia, metallic implants, particularly intraocular implants, pacemakers)
- Contraindications to magnetoencephalography (MEG) (metallic implants in the mouth-dentures, fillings, crowns)
- Coagulation disorders
- Pregnancy, breastfeeding, or patients not using effective contraception
- Subjects participating in another interventional study with an exclusion period still in progress at the time of pre-inclusion, etc.
- Subjects deprived of their liberty by judicial or administrative decision
- Subjects receiving psychiatric care
- Subjects admitted to a health or social care facility for purposes other than research
- Adult subjects subject to legal protection measures (guardianship, curatorship)
- Subjects not affiliated with a social security system or beneficiaries of a similar system
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- Hospices Civils de Lyon — Bron
Identifiers
NCT: NCT07616726 · 69HCL26_0020 · 2026-A01156-45